<DOC>
	<DOCNO>NCT02422719</DOCNO>
	<brief_summary>The purpose study determine whether radotinib effective safe patient chronic myeloid leukemia , chronic phase intolerable resistant prior 2 tyrosine kinase inhibitor .</brief_summary>
	<brief_title>Radotinib 3rd Later Line Therapy CP-CML</brief_title>
	<detailed_description>The purpose study determine whether radotinib 400mg bid effective safe patient chronic myeloid leukemia , chronic phase intolerable resistant prior 2 tyrosine kinase inhibitor . The primary end point major cytogenetic response 12 month .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<criteria>Chronic myeloid leukemia chronic phase ( CPCML ) patient tolerable resistant prior 2 tyrosine kinase inhibitor ( TKIs ) . ECOG 0 , 1 , 2 Patients agree sign informed consent . T315I mutation Prior exposure radotinib Accelerated blastic phase galactose intolerance , severe lactase deficiency glucose galactose malabsorption Prior history intensive cytotoxic chemotherapy except TKIs Significant cardiac problem QTcF &gt; 450 msec Pancreatitis history prior study enrollment Clinically significant malignant disease CML Pregnant breast feed woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Chronic myeloid leukemia</keyword>
	<keyword>Intolerance</keyword>
	<keyword>Resitance</keyword>
	<keyword>Radotinib</keyword>
</DOC>